Browse

Reference

Directory

Company

Help & Legal

Follow

Subscribe

Quick Take

Google DeepMind announced AlphaGenome 2 on Nov. 11, 2026, a DNA prediction model designed to show how genetic changes act in specific cell types and states. The approach aims to expose disease-linked effects that broad tissue measurements can obscure, giving scientists a more focused starting point for experiments.

The original AlphaGenome produced fixed parallel outputs across tissues and experiments from a million-letter DNA sequence. AlphaGenome 2 instead takes a target condition, such as a tissue, cell type or cell state, alongside the sequence and uses that condition throughout its architecture, according to DeepMind.

Its announcement pairs a reported improvement on an immune-cell benchmark with a computational reproduction of an established bowel-disease mechanism. The examples show how the model could focus laboratory work on particular variants and cells.

DeepMind’s AI humanoids are already doing factory work at Mercedes

That allows predictions to ask how the same stretch of DNA behaves in different cellular settings. DeepMind says this can help identify effects confined to particular cells that broader tissue models miss. A tissue-level result can provide useful context while still leaving the cell responsible for a disease-linked effect unresolved.

The cell context changes the DNA question

AlphaGenome 2 combines DNA with a target cell type or state to predict effects in that setting.

Cell-specific predictions can focus experiments on effects broad tissue averages may miss.

Company-reported research predictions. The ETS2 mechanism predates this model. AlphaGenome 2 has not been validated or approved for clinical or diagnostic use.

Sources

Supporting facts

Method

Qualitative input-to-prediction schematic using the reported model design, plus DeepMind's retrospective ETS2 example. Shapes, distances and cell symbols encode relationships, not measured signal magnitudes, cell counts or effect sizes.

Scope

The company reports training the model on bulk and single-cell data from human and mouse samples, including more than 107 million individual cell profiles. The profiles supply training material for learning how DNA activity varies across biological settings.

DeepMind also says researchers can supply single-cell gene-activity data to condition predictions on newly observed states without retraining the model. The system can then predict properties that were not measured, helping scientists decide which experiments to prioritize.

On TenK10K, a dataset covering 28 primary immune-cell types, DeepMind reports that AlphaGenome 2 identified 30% of causal variants in the evaluation, compared with 16% for the original AlphaGenome fine-tuned on single-cell data.

These developer-reported benchmark results measure variant identification, not diagnostic accuracy or a person’s disease risk.

For researchers, the practical attraction is a larger set of candidate variants to investigate in the cells where they may act. Connecting a disease-associated genetic signal to a particular variant, target gene and cell type can make the next experiment more focused.

AI agents just completed a four-day cryptography test with only 20 human messages needed – DeepMind says

Reproducing an existing disease clue

The bowel-disease example makes the distinction concrete. In its Nov. 11 announcement, DeepMind says AlphaGenome 2 computationally reproduced a finding involving a regulatory variant that increases activity of the ETS2 gene in gut macrophages, a type of immune cell.

The model singled out the variant and predicted its selective effect on ETS2 in those macrophages, with other cell types and genes largely unaffected. The useful clue is the combination of variant, gene and cell type: it points to a specific cellular setting for investigating the effect.

The underlying biology predates this model. In a June 7, 2024 report, Imperial College London described research conducted with the Francis Crick Institute and UCL that linked a macrophage-active regulatory region to increased ETS2 activity and inflammatory functions. The biological mechanism was therefore already established; AlphaGenome 2's contribution in this example is reproducing it computationally.

As of the Nov. 11 announcement, DeepMind offered AlphaGenome 2 through its API for non-commercial research, with commercial research in private preview. The company states that both AlphaGenome models are intended for research and have not been validated or approved for clinical or diagnostic purposes.

Google AI can now spot high blood pressure using ordinary watch sensors

The immediate opportunity is to choose better-targeted experiments: investigate a genetic change in the cell type or state where its effect is predicted to appear.

Anthropic’s new AI leads freelance benchmarks, yet fails 58% of the tasks

Cookie Consent

We use cookies to improve your experience on our site. By using our site, you consent to cookies.

Cookie Preferences

Manage your cookie preferences below:

Essential cookies enable basic functions and are necessary for the proper function of the website.

CloudFlare provides web performance and security solutions, enhancing site speed and protecting against threats.

Service URL: developers.cloudflare.com (opens in a new window)

Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.

Service URL: policies.google.com (opens in a new window)

Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.

Clarity is a web analytics service that tracks and reports website traffic.

Service URL: clarity.microsoft.com (opens in a new window)

You can find more information in our Privacy Policy and .

Loading image…

This image could not be loaded.

The Catalyst